Objective To develop a risk prediction model for severe adenovirus pneumonia (AVP) in children, and to explore the appropriate timing for intravenous immunoglobulin (IVIG) therapy for severe AVP. Methods Medical data of 1 046 children with AVP were retrospectively analyzed, and a risk prediction model for severe AVP was established using multivariate logistic regression. The model was validated with 102 children with AVP. Then, 75 children aged ≤14 years who were considered at risk of developing severe AVP by the model were prospectively enrolled and divided into three groups (A, B and C) in order of visit, with 25 children in each group. Group A received symptomatic supportive therapy only. With the exception of symptomatic supportive therapy, group B received IVIG treatment at a dose of 1g/(kg·d) for 2 consecutive days, before progressing to severe AVP. With the exception of symptomatic supportive therapy, group C received IVIG treatment at a dose of 1 g/(kg·d) for 2 consecutive days after progressing to severe AVP. Efficacy and related laboratory indicators were compared among the three groups after treatment. Results Age<18.5 months, underlying diseases, fever duration >6.5 days, hemoglobin level <84.5 g/L, alanine transaminase level >113.5 U/L, and co-infection with bacteria were the six variables that entered into the risk prediction model for severe AVP. The model had an area under the receiver operating characteristic curve of 0.862, sensitivity of 0.878, and specificity of 0.848. The Hosmer-Lemeshow test showed good consistency between the predicted values and the actual observations (P>0.05). After treatment, group B had the shortest fever duration and hospital stay, the lowest hospitalization costs, the highest effective rate of treatment, the lowest incidence of complications, the lowest white blood cell count and interleukin (IL)-1, IL-2, IL-6, IL-8, IL-10 levels, and the highest level of tumor necrosis factor alpha (P<0.05). Conclusions The risk model for severe AVP established in this study has good value in predicting the development of severe AVP. IVIG therapy before progression to severe AVP is more effective in treating AVP in children.
Key words
Adenoviral pneumonia /
Risk model /
Intravenous immunoglobulin /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 刘秀云, 江载芳. 小儿重症社区获得性肺炎31例病原分析[J]. 中国实用儿科杂志, 2005, 20(12): 749-750. DOI: 10.3969/j.issn.1005-2224.2005.12.019.
2 Hong JY, Lee HJ, Piedra PA, et al. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis[J]. Clin Infect Dis, 2001, 32(10): 1423-1429. PMID: 11317242. DOI: 10.1086/320146.
3 蒲开彬, 黄英, 舒畅, 等. 静脉用丙种球蛋白辅助治疗儿童重症腺病毒肺炎回顾性分析[J]. 临床儿科杂志, 2014, 32(5): 449-452. DOI: 10.3969/j.issn.1000-3606.2014.05.013.
4 樊慧峰, 陈晨, 徐雪花, 等. 静脉注射丙种球蛋白在重症腺病毒肺炎患儿中的应用策略[J]. 中华实用儿科临床杂志, 2022, 37(9): 671-675. DOI: 10.3760/cma.j.cn101070-20210402-00385.
5 邓俊超, 朱小石. 儿童重症腺病毒肺炎临床特征及丙种球蛋白辅助治疗效果分析[J]. 临床误诊误治, 2018, 31(5): 86-89. DOI: 10.3969/j.issn.1002-3429.2018.05.023.
6 中华人民共和国国家卫生健康委员会国家中医药管理局. 儿童腺病毒肺炎诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(3): 161-166. DOI: 10.3760/cma.j.issn.1674-2397.2019.03.001.
7 中华人民共和国国家健康委员会, 国家中医药局. 儿童社区获得性肺炎诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(1): 6-13. DOI: 10.3760/cma.j.issn.1674-2397.2019.01.002.
8 宋国维. 小儿危重病例评分[J]. 中华急诊医学杂志, 2003, 12(5): 359-360. DOI: 10.3760/j.issn:1671-0282.2003.05.039.
9 崔赢, 栾兰, 黄瑞. 静脉输注人免疫球蛋白不良反应的临床特点[J]. 实用药物与临床, 2015, 18(12): 1490-1493. DOI: 10.14053/j.cnki.ppcr.201512026.
10 Bhutta ZA, Das JK, Walker N, et al. Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost?[J]. Lancet, 2013, 381(9875): 1417-1429. PMID: 23582723. DOI: 10.1016/S0140-6736(13)60648-0.
11 Agweyu A, Kibore M, Digolo L, et al. Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines[J]. Trop Med Int Health, 2014, 19(11): 1310-1320. PMID: 25130866. PMCID: PMC4241029. DOI: 10.1111/tmi.12368.
12 Lynch JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention[J]. Semin Respir Crit Care Med, 2016, 37(4): 586-602. PMID: 27486739. PMCID: PMC7171713. DOI: 10.1055/s-0036-1584923.
13 Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment[J]. Curr Infect Dis Rep, 2014, 16(8): 416. PMID: 24908344. DOI: 10.1007/s11908-014-0416-y.
14 Li L, Woo YY, de Bruyne JA, et al. Epidemiology, clinical presentation and respiratory sequelae of adenovirus pneumonia in children in Kuala Lumpur, Malaysia[J]. PLoS One, 2018, 13(10): e0205795. PMID: 30321228. PMCID: PMC6188781. DOI: 10.1371/journal.pone.0205795.
15 何蕾, 江剑民, 陈建愉, 等. 儿童腺病毒肺炎临床特点及感染发生预测模型构建[J]. 广西医科大学学报, 2022, 39(9): 1414-1418. DOI: 10.16190/j.cnki.45-1211/r.2022.09.010.
16 姚国华, 马翠安, 刘杰, 等. 基于随机森林算法的儿童重症腺病毒肺炎临床预测模型研究[J]. 国际儿科学杂志, 2022, 49(8): 566-569. DOI: 10.3760/cma.j.issn.1673-4408.2022.08.014.
17 谭江宁, 韩玲. 免疫球蛋白免疫调节机制的研究进展[J]. 中国实用儿科杂志, 2004, 19(5): 308-310. DOI: 10.3969/j.issn.1005-2224.2004.05.025.
18 Atasheva S, Shayakhmetov DM. Cytokine responses to adenovirus and adenovirus vectors[J]. Viruses, 2022, 14(5): 888. PMID: 35632630. PMCID: PMC9145601. DOI: 10.3390/v14050888.
19 Li J, Wei J, Xu Z, et al. Cytokine/chemokine expression is closely associated disease severity of human adenovirus infections in immunocompetent adults and predicts disease progression[J]. Front Immunol, 2021, 12: 691879. PMID: 34163488. PMCID: PMC8215364. DOI: 10.3389/fimmu.2021.691879.
20 樊慧峰, 卢秉泰, 黄莉, 等. 儿童腺病毒肺炎患儿部分细胞因子水平及临床意义[J]. 贵州医科大学学报, 2019, 44(5): 606-611. DOI: 10.19367/j.cnki.1000-2707.2019.05.022.
PDF(640 KB)
